One in three people will develop cancer during their lives and this incidence is expected to increase. The challengeis is that each patient responds to drugs differently, and determining treatment efficacy for cancer patients can take between 3 to 9 months. Unfortunately, some patients die because of treatment inefficacy. The inadequate correlation between preclinical in vitro and in vivo data and individual patient outcomes remains a significant gap that needs to be closed.
An emerging technology for personalised medicine is Tumour-on-a-chip. The advanced Tumour-on-a-chip model we provide, named BioTwin Chip, can grow patient tumour tissues outside of the human body, analyse the therapeutic killing effect on tumour tissues, and predict treatment efficacy within weeks. The BioTwin Chip aims to harness the predictive power of patient microtissues derived from tumour biopsies..
The BioTwin Chip takes the key elements of a person’s biological system to recreate a ’biological twin’, forming a 3D cell structure rapidly to optimise and test personalised precision medicine. This tissue culture platform can grow cell lines, organoids and primary tissues for testing various cancer types coupled with personalised treatment recommendations.
Mouse Mammary Tissue
Brain Organoid
Gut Tissue
Angiogenesis
Glioblastoma
Drug testing
